logo-loader
viewShield Therapeutics PLC

Shield Therapeutics announces appointment of Hans Peter Hasler as its non-executive chairman from June 18

The group announced on May 21 that its current chairman, James Karis would not seek re-election and would be stepping down at the AGM

Shield Therapeutics PLC -

Shield Therapeutics PLC (LON:STX) has announced the appointment of Hans Peter Hasler as the company’s non-executive chairman with effect from its annual general meeting (AGM) to be held on June 18, 2020.

The commercial stage, pharmaceutical company, with a focus on addressing iron deficiency with its lead product Feraccru/Accrufer (ferric maltol) announced on May 21 that its current chairman, James Karis would not seek re-election and would be stepping down at the AGM.

READ: Shield Therapeutics CEO says finding a US partner for lead drug is "top priority" for 2020

It noted that Hasler joined Shield's board of directors in July 2018 and has served as chairman of the Nomination Committee and a member of the Audit Committee. 

He has prior executive experience including as chief operating officer at both Elan Corporation and Biogen Inc. as well as chief marketing officer of Wyeth Pharmaceuticals, and is currently non-executive chairman of HBM Healthcare Investments AG, Zug/Switzerland and a non-executive director of Minerva Neuroscience Inc., the group added.

In a statement, Tim Watts, CEO of Shield Therapeutics, commented: "I am very pleased to see Hans Peter appointed as our Chairman. I have worked increasingly closely with Hans Peter over the last two years and value his experience and insights and the support he has given me personally."

Hasler added: "I am delighted to have been appointed as Chairman of Shield at a critical time for the Group. Feraccru/ Accrufer is an excellent product with enormous potential and I look forward to continuing to help the Group find ways of making it available to the widest possible number of patients and to translating that into value for shareholders. I also look forward to working with the rest of the Board and the management team in these endeavours."

Quick facts: Shield Therapeutics PLC

Price: 85.5 GBX

LSE:STX
Market: LSE
Market Cap: £100.2 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Shield Therapeutics PLC: Proactive One2One Virtual Event

Shield Therapeutics PLC's (LON:STX) Tim Watts pitches the company to investors at the Proactive One2One Virtual Event. Shield is a de-risked, commercial stage, specialty pharmaceutical company delivering innovative pharmaceuticals to address patients' unmet medical needs. The Group’s lead...

on 8/6/20

2 min read